Insulet Corporation ( NASDAQ:PODD ) saw a double-digit share price rise of over 10% in the past couple of months on ...

Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet (PODD – Research Report) yesterday and set a price target of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Unlike most of her Senate colleagues involved in the stock market, Minnesota's Tina Smith maintains a unique portfolio.

Insulet (NASDAQ:PODD – Get Free Report) had its target price increased by investment analysts at TD Cowen from $264.00 to ...

Intuitive Surgical (ISRG), and Insulet (PODD) stocks were cited as top MedTech stock picks for 2025 by J.P. Morgan. Read more ...

Buying $100 In PODD: If an investor had bought $100 of PODD stock 10 years ago, it would be worth $598.02 today based on a ...

TD Cowen raised the firm’s price target on Insulet (PODD) to $324 from $264 and keeps a Buy rating on the shares. The firm thinks Insulet will ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for those with Type 2 diabetes. The system ...